ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1000

Molecular Mechanism of Inhibition of CD38 in Attenuation of Monosodium Urate Crystal-induced Inflammatory Responses in Macrophages

Huaping Qin1, Patricia Oliveira1, Tiffany Yan1, Robert Terkeltaub2 and Ru Liu Bryan3, 1University of California San Diego, La Jolla, CA, 2VA/UCSD, San Diego, CA, 3University of California San Diego and VASDHS, San Diego, CA

Meeting: ACR Convergence 2021

Keywords: cytokines, Gene Expression, gout, Inflammation, macrophages

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 8, 2021

Title: Innate Immunity Poster (0992–1006)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: CD38 can function as a degrading enzyme of nicotinamide adenine dinucleotide (NAD), a critical metabolic intermediate serving as enzyme cofactor in redox reactions and as a co-substrate by many enzymes such as sirtuins (SIRTs). We have recently observed that expression of CD38 is increased in PBMCs of gout patients compared to health controls, and inhibition of CD38 attenuated monosodium urate (MSU) crystal-induced acute inflammatory responses in mice in vivo. In this study, we investigated the molecular mechanism mediating beneficial effect of inhibition of CD38 in macrophages in response to MSU crystals in vitro.

Methods: Bone marrow derived macrophages (BMDMs) prepared from CD38 knockout (KO) and wild type (WT) were treated with MSU crystals (0.2 mg/ml) in the presence or absence of apigenin (25 μM), a flavonoid that selectively inhibits CD38 for 6 and 24 hours. Expression of CD38 was examined at both mRNA and protein levels by qRT-PCR and Western blot analysis. The NADH/NAD Quantification Kit (BioVision) was used to measure the intracellular NAD, NADH and their ratio. Western blot analysis was carried out to examine expression of NAD-dependent SIRT3 and acetylated SOD2, expression of NLRP3 and cleaved caspase-1. ELISA was performed to determine the release of IL-1β from the conditioned media. RNA sequencing analysis was also carried out to profile differentially expressed genes.

Results: The NAD/NADH ratio was significantly reduced in BMDMs treated with MSU crystals at both 6 and 24 hours, correlated with increased CD38 expression at both mRNA and protein levels, respectively. Apigenin inhibited CD38 expression, prevented a decrease in NAD/NADH ratio, prohibited a decrease in expression of SIRT3 and an increase in expression of acetylated SOD2, an antioxidant enzyme in the mitochondria, in BMDMs treated with MSU crystals. Apigenin also suppressed NLRP3 expression at both mRNA and protein levels, inhibited expression of cleaved casepase-1, and attenuated IL-1ß release in response to MSU crystals. RNA-seq analysis showed that 163 genes upregulated in WT+MSU BMDMs (log2FC≥1)were downregulated in both WT+MSU+apigenin and CD38KO BMDMs (log2FC≤1). KEGG Pathway enrichment analysis revealed several inflammatory pathways including cytokine-cytokine receptor interaction, chemokine, TNF, NF-κB, JAK-STAT, HIF-1α, TLR and MAPK signaling. Interestingly, a top differentially expressed gene six-transmembrane epithelial antigen of prostate 4 (Steap4) was upregulated in WT+MSU BMDMs (log2FC=8.14) but was downregulated in WT+MSU+apigenin BMDMs (log2FC= –7.18) and CD38KO+MSU BMDMs (log2FC= –4.43). Steap4 is a metalloreductase that has the ability to reduce both Fe(3+) to Fe(2+) and Cu(2+) to Cu(1+), using NAD(+) as acceptor. Increased Steap4 expression has been shown to lead to mitochondrial iron accumulation and enhanced reactive oxygen species production. Thus, downregulation of Steap4 expression induced by MSU crystals through inhibition of CD38 may help maintain mitochondria homeostasis.

Conclusion: Inhibition of CD38 can attenuate inflammatory response to MSU crystals in macrophages by prohibiting NAD decline and preventing mitochondrial dysfunction.

Figure 1. Induction of CD38 expression by MSU crystals correlated with decreased NAD/NADH ratio in mouse BMDMs.

Figure 2. Apigenin inhibited CD38 expression, prevented a decrease in NAD/NADH ratio, prohibited a decrease in expression of SIRT3 and an increase in expression of acetylated SOD2, suppressed NLRP3 expression at both mRNA and protein levels, inhibited expression of cleaved casepase_1, and attenuated IL_1b release in response to MSU crystals in macrophages.


Disclosures: H. Qin, None; P. Oliveira, None; T. Yan, None; R. Terkeltaub, SOBI, 2, Selecta, 2, Allena, 2, Horizon, 2, Astra-Zeneca, 2, Astra-Zeneca, 5; R. Liu Bryan, None.

To cite this abstract in AMA style:

Qin H, Oliveira P, Yan T, Terkeltaub R, Liu Bryan R. Molecular Mechanism of Inhibition of CD38 in Attenuation of Monosodium Urate Crystal-induced Inflammatory Responses in Macrophages [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/molecular-mechanism-of-inhibition-of-cd38-in-attenuation-of-monosodium-urate-crystal-induced-inflammatory-responses-in-macrophages/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/molecular-mechanism-of-inhibition-of-cd38-in-attenuation-of-monosodium-urate-crystal-induced-inflammatory-responses-in-macrophages/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology